Probiotic complex administration experience in treatment of diabetes mellitus type 2 patients
The results of the randomized open single-center study in patients with diabetes type 2 are presented. Metabolic efficiency and safety of dietary supplement «Baktistatin» were studied during one month in complex with combined sugar- reducing therapy and lipid-lowering therapy (triple therapy) compared to metformin and simvastatin therapy (double therapy). The triple therapy was shown to have metabolically neutral effect over the lipid and carbohydrate profile and not to cause adverse effects. Double therapy causes decrease of lactobacillus within the intestinal microbiota, assessed as 1st degree dysbiosis. Administration of pre- and probiotical dietary supplement combined with metformin and simvastatin preventive effect over intestinal dysbiosis was assessed by microbiological analysis. However the shift in the intestinal flora quantitative balance, even within the limits of reference values, in these patients was paid-off by clinical symptoms of eructation, abdominal pain, feeling of incomplete bowel emptying and imperative feeling of defecation within short-term period. Which probably indicates no necessity of long-term treatment using the specified probiotic with metformin and simvastatin therapy background. Diabetes type 2 patients treatment using probiotics should be strictly based on indications. Prospective studies of clinical and laboratory effectiveness and safety of modern probiotics offered by the market, specification of their mechanism of action, comparison of different administration modes will let us widen our understanding of complicated interaction between intestinal microflora and chronic hyperglycemia. Those efforts should stimulate development of new effective therapeutic approaches in diabetes type 2 patients treatment.